{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T01:02:21Z","timestamp":1779670941925,"version":"3.53.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":51,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Changzhou \u201c14th Five-Year Plan\u201d Key Disciplines"},{"name":"Changzhou \u201c14th Five-Year Plan\u201d Health Leading Talents Training Project"},{"name":"Hospital, Changzhou Medical Center, NanjingMedical University"},{"name":"Key project of Jiangsu Province HealthCommittee"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02135-1","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T09:43:07Z","timestamp":1775295787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A DLBCL Prognostic model superior to the IPI score: Mechanistic study and clinical validation based on RFC2- and RFC4-mediated DNA damage repair"],"prefix":"10.1007","volume":"26","author":[{"given":"Shuainan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laibing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luo","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0311-7074","authenticated-orcid":false,"given":"Tongbing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4913-1610","authenticated-orcid":false,"given":"Weiying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"issue":"3","key":"2135_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/ajh.1102","volume":"67","author":"DD Weisenburger","year":"2001","unstructured":"Weisenburger DD, et al. Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin\u2019s lymphoma classification project. Am J Hematol. 2001;67(3):172\u20138.","journal-title":"Am J Hematol"},{"issue":"6769","key":"2135_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expressionprofiling. Nature. 2000;403(6769):503.","journal-title":"Nature"},{"issue":"3","key":"2135_CR3","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1182\/blood.V99.3.815","volume":"99","author":"M Yamaguchi","year":"2002","unstructured":"Yamaguchi M, et al. De novo CD5\u2009+\u2009diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood. 2002;99(3):815\u201321.","journal-title":"Blood"},{"issue":"5","key":"2135_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00277-003-0812-0","volume":"83","author":"A Isikdogan","year":"2004","unstructured":"Isikdogan A, et al. Non-Hodgkin\u2019s lymphoma in southeast Turkey: clinicopathologic features of 490 cases. Ann Hematol. 2004;83(5):265\u20139.","journal-title":"Ann Hematol"},{"key":"2135_CR5","first-page":"p5231","volume":"130","author":"M Kim","year":"2017","unstructured":"Kim M, et al. Difference of Clinical Parameters between GCB and Non-GCB Subtype DLBCL. Blood. 2017;130:p5231\u20135231.","journal-title":"Blood"},{"issue":"4","key":"2135_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4103\/jmau.jmau_66_22","volume":"12","author":"L Dhar","year":"2024","unstructured":"Dhar L, et al. Cell of Origin Classification of Diffuse Large B-Cell Lymphoma. J Microscopy Ultrastructure. 2024;12(4):193\u20138.","journal-title":"J Microscopy Ultrastructure"},{"issue":"19","key":"2135_CR7","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","volume":"24","author":"TM Habermann","year":"2006","unstructured":"Habermann TM, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2135_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235.","journal-title":"N Engl J Med"},{"issue":"16","key":"2135_CR9","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u20138.","journal-title":"Blood"},{"issue":"1","key":"2135_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-025-01702-5","volume":"18","author":"AM Bock","year":"2025","unstructured":"Bock AM, Epperla N. Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies. J Hematol Oncol. 2025;18(1):68.","journal-title":"J Hematol Oncol"},{"key":"2135_CR11","doi-asserted-by":"crossref","unstructured":"Shipp M. A Predictive Model for Aggressive Non-Hodgkin\u2019s Lymphoma. N Engl J Med, 1993. 329.","DOI":"10.1056\/NEJM199309303291402"},{"issue":"7","key":"2135_CR12","doi-asserted-by":"publisher","first-page":"e70190","DOI":"10.1002\/mco2.70190","volume":"6","author":"L Mi","year":"2025","unstructured":"Mi L, et al. Genetic Subtype-Based International Prognostic Index Prognostic Model in Diffuse Large B-Cell Lymphoma. MedComm. 2025;6(7):e70190\u201370190.","journal-title":"MedComm"},{"key":"2135_CR13","doi-asserted-by":"crossref","unstructured":"Zhang F et al. Comparative investigation among fluorescence in situ hybridization, DNA- and RNA-sequencing on detecting MYC, BCL2, and BCL6 rearrangements in high-grade B-cell lymphomas. Neoplasma, 2024. 71(5).","DOI":"10.4149\/neo_2024_240527N236"},{"key":"2135_CR14","unstructured":"Cui J et al. Development and validation of a prognostic nomogram for diffuse large B-cell lymphoma: a multicenter cohort study from Northern China. Clinical and Translational Oncology: pp. 1\u201311."},{"issue":"9","key":"2135_CR15","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.1128\/MCB.15.9.4661","volume":"15","author":"G Cullmann","year":"1995","unstructured":"Cullmann G, et al. Characterization of the five replication factor C genes of Saccharomyces cerevisiae. Mol Cell Biol. 1995;15(9):4661\u201371.","journal-title":"Mol Cell Biol"},{"key":"2135_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/978-94-007-4572-8_14","volume":"62","author":"NY Yao","year":"2012","unstructured":"Yao NY, O\u2019Donnell M. The RFC clamp loader: structure and function. Subcell Biochem. 2012;62:259\u201379.","journal-title":"Subcell Biochem"},{"issue":"2","key":"2135_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jmb.2011.12.017","volume":"416","author":"M Sakato","year":"2012","unstructured":"Sakato M, O\u2019Donnell M, Hingorani MM. A central swivel point in the RFC clamp loader controls PCNA opening and loading on DNA. J Mol Biol. 2012;416(2):163\u201375.","journal-title":"J Mol Biol"},{"key":"2135_CR18","doi-asserted-by":"crossref","unstructured":"Misbah M et al. Identification of expression profiles and prognostic value of RFCs in colorectal cancer. Sci Rep, 2024. 14(1).","DOI":"10.1038\/s41598-024-56361-2"},{"issue":"6","key":"2135_CR19","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1021\/acs.jproteome.4c00885","volume":"24","author":"A Mukherjee","year":"2025","unstructured":"Mukherjee A, et al. Investigating Cisplatin Resistance in Squamous Cervical Cancer: Proteomic Insights into DNA Repair Pathways and Omics-Based Drug Repurposing. J Proteome Res. 2025;24(6):2628\u201342.","journal-title":"J Proteome Res"},{"issue":"37","key":"2135_CR20","doi-asserted-by":"publisher","first-page":"34792","DOI":"10.1074\/jbc.M011671200","volume":"276","author":"SL Schmidt","year":"2001","unstructured":"Schmidt SL, Pautz AL, Burgers PM. ATP utilization by yeast replication factor C. IV. RFC ATP-binding mutants show defects in DNA replication, DNA repair, and checkpoint regulation. J Biol Chem. 2001;276(37):34792\u2013800.","journal-title":"J Biol Chem"},{"issue":"1","key":"2135_CR21","doi-asserted-by":"publisher","first-page":"23264","DOI":"10.1038\/s41598-021-02773-3","volume":"11","author":"L Bermudez-Guzman","year":"2021","unstructured":"Bermudez-Guzman L. Pan-cancer analysis of non-oncogene addiction to DNA repair. Sci Rep. 2021;11(1):23264.","journal-title":"Sci Rep"},{"issue":"1","key":"2135_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s40478-025-02046-4","volume":"13","author":"H Li","year":"2025","unstructured":"Li H, et al. Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights. Acta Neuropathol Commun. 2025;13(1):126.","journal-title":"Acta Neuropathol Commun"},{"key":"2135_CR23","doi-asserted-by":"crossref","unstructured":"Zheng F et al. Cryo-EM structures reveal that RFC recognizes both the 3\u2019- and 5\u2019-DNA ends to load PCNA onto gaps for DNA repair. Elife, 2022. 11.","DOI":"10.7554\/eLife.77469"},{"issue":"23","key":"2135_CR24","doi-asserted-by":"publisher","first-page":"13738","DOI":"10.18632\/aging.205260","volume":"15","author":"J Zhu","year":"2023","unstructured":"Zhu J, et al. Involvement of RFC3 in tamoxifen resistance in ER-positive breast cancer through the cell cycle. Aging. 2023;15(23):13738\u201352.","journal-title":"Aging"},{"issue":"1","key":"2135_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s41065-021-00179-9","volume":"158","author":"Z Ji","year":"2021","unstructured":"Ji Z, Li J, Wang J. Up-regulated RFC2 predicts unfavorable progression in hepatocellular carcinoma. Hereditas. 2021;158(1):17.","journal-title":"Hereditas"},{"issue":"14","key":"2135_CR26","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1158\/1078-0432.CCR-18-3735","volume":"25","author":"XC Wang","year":"2019","unstructured":"Wang XC, et al. Genome-wide RNAi Screening Identifies RFC4 as a Factor That Mediates Radioresistance in Colorectal Cancer by Facilitating Nonhomologous End Joining Repair. Clin Cancer Res. 2019;25(14):4567\u201379.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2135_CR27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s12916-022-02630-8","volume":"20","author":"J Zhang","year":"2022","unstructured":"Zhang J, et al. Sequential gene expression analysis of cervical malignant transformation identifies RFC4 as a novel diagnostic and prognostic biomarker. BMC Med. 2022;20(1):437.","journal-title":"BMC Med"},{"key":"2135_CR28","doi-asserted-by":"crossref","unstructured":"Chaudhari J, Shah NN. Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma. Cancers (Basel), 2025. 17(15).","DOI":"10.3390\/cancers17152517"},{"issue":"10","key":"2135_CR29","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1182\/bloodadvances.2022009389","volume":"7","author":"PWM Johnson","year":"2023","unstructured":"Johnson PWM, et al. Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial. Blood Adv. 2023;7(10):2008\u201317.","journal-title":"Blood Adv"},{"issue":"3","key":"2135_CR30","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","volume":"6","author":"WS Kim","year":"2025","unstructured":"Kim WS, et al. Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial. Nat Cancer. 2025;6(3):528\u201339.","journal-title":"Nat Cancer"},{"issue":"1","key":"2135_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41408-025-01318-5","volume":"15","author":"F St-Pierre","year":"2025","unstructured":"St-Pierre F, et al. Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma-Results from a multicenter cohort study. Blood Cancer J. 2025;15(1):110.","journal-title":"Blood Cancer J"},{"issue":"2","key":"2135_CR32","first-page":"141","volume":"142","author":"PL Zinzani","year":"2023","unstructured":"Zinzani PL, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood. 2023;142(2):141\u20135.","journal-title":"Blood"},{"issue":"8","key":"2135_CR33","first-page":"1343","volume":"8","author":"Y Li","year":"2018","unstructured":"Li Y, et al. Multifaceted regulation and functions of replication factor C family in human cancers. Am J Cancer Res. 2018;8(8):1343\u201355.","journal-title":"Am J Cancer Res"},{"issue":"9","key":"2135_CR34","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1002\/ijc.33049","volume":"147","author":"S Jiang","year":"2020","unstructured":"Jiang S, et al. Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup. Int J Cancer. 2020;147(9):2611\u201320.","journal-title":"Int J Cancer"},{"issue":"4","key":"2135_CR35","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1073\/pnas.1205299110","volume":"110","author":"J Zhang","year":"2013","unstructured":"Zhang J, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2013;110(4):1398\u2013403.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2135_CR36","first-page":"382","volume":"20","author":"Z Fan","year":"2020","unstructured":"Fan Z, et al. Comprehensive characterization of driver genes in diffuse large B cell lymphoma. Oncol Lett. 2020;20(1):382\u201390.","journal-title":"Oncol Lett"},{"issue":"10","key":"2135_CR37","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.7150\/ijbs.93349","volume":"20","author":"QX Liu","year":"2024","unstructured":"Liu QX, et al. KMT2D mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-induced regulatory T cell trafficking via FBXW7-NOTCH-MYC\/TGF-beta1 axis. Int J Biol Sci. 2024;20(10):3972\u201385.","journal-title":"Int J Biol Sci"},{"issue":"15","key":"2135_CR38","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.7150\/jca.75813","volume":"13","author":"M He","year":"2022","unstructured":"He M, et al. B2M mutation paves the way for immune tolerance in pathogenesis of Epstein-Barr virus positive diffuse large B-cell lymphomas. J Cancer. 2022;13(15):3615\u201322.","journal-title":"J Cancer"},{"issue":"52","key":"2135_CR39","doi-asserted-by":"publisher","first-page":"E7230","DOI":"10.1073\/pnas.1507459112","volume":"112","author":"N Knies","year":"2015","unstructured":"Knies N, et al. Lymphomagenic CARD11\/BCL10\/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-kappaB and JNK activation. Proc Natl Acad Sci U S A. 2015;112(52):E7230\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2135_CR40","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1111\/cas.13057","volume":"107","author":"T Takahara","year":"2016","unstructured":"Takahara T, et al. Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model. Cancer Sci. 2016;107(11):1572\u201380.","journal-title":"Cancer Sci"},{"issue":"20","key":"2135_CR41","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1182\/blood.2020005244","volume":"137","author":"M Reimann","year":"2021","unstructured":"Reimann M, et al. Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas. Blood. 2021;137(20):2785\u201399.","journal-title":"Blood"},{"issue":"12","key":"2135_CR42","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1038\/s12276-020-00533-3","volume":"52","author":"KY Lee","year":"2020","unstructured":"Lee KY, Park SH. Eukaryotic clamp loaders and unloaders in the maintenance of genome stability. Exp Mol Med. 2020;52(12):1948\u201358.","journal-title":"Exp Mol Med"},{"issue":"20","key":"2135_CR43","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.1128\/MCB.00285-10","volume":"30","author":"RM Overmeer","year":"2010","unstructured":"Overmeer RM, et al. Replication factor C recruits DNA polymerase delta to sites of nucleotide excision repair but is not required for PCNA recruitment. Mol Cell Biol. 2010;30(20):4828\u201339.","journal-title":"Mol Cell Biol"},{"issue":"6708","key":"2135_CR44","doi-asserted-by":"publisher","first-page":"eadk5901","DOI":"10.1126\/science.adk5901","volume":"385","author":"Z Yuan","year":"2024","unstructured":"Yuan Z, et al. Mechanism of PCNA loading by Ctf18-RFC for leading-strand DNA synthesis. Science. 2024;385(6708):eadk5901.","journal-title":"Science"},{"issue":"11","key":"2135_CR45","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/s41594-024-01332-4","volume":"31","author":"F Wang","year":"2024","unstructured":"Wang F, et al. The human ATAD5 has evolved unique structural elements to function exclusively as a PCNA unloader. Nat Struct Mol Biol. 2024;31(11):1680\u201391.","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"2135_CR46","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1038\/s41467-019-10376-w","volume":"10","author":"MS Kang","year":"2019","unstructured":"Kang MS, et al. Regulation of PCNA cycling on replicating DNA by RFC and RFC-like complexes. Nat Commun. 2019;10(1):2420.","journal-title":"Nat Commun"},{"issue":"14","key":"2135_CR47","doi-asserted-by":"publisher","first-page":"8279","DOI":"10.1093\/nar\/gkac588","volume":"50","author":"M Day","year":"2022","unstructured":"Day M, Oliver AW, Pearl LH. Structure of the human RAD17-RFC clamp loader and 9-1-1 checkpoint clamp bound to a dsDNA-ssDNA junction. Nucleic Acids Res. 2022;50(14):8279\u201389.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"2135_CR48","doi-asserted-by":"publisher","first-page":"103061","DOI":"10.1016\/j.jbc.2023.103061","volume":"299","author":"K Hara","year":"2023","unstructured":"Hara K, et al. The 9-1-1 DNA clamp subunit RAD1 forms specific interactions with clamp loader RAD17, revealing functional implications for binding-protein RHINO. J Biol Chem. 2023;299(4):103061.","journal-title":"J Biol Chem"},{"issue":"26","key":"2135_CR49","doi-asserted-by":"publisher","first-page":"28311","DOI":"10.1021\/acsomega.5c03331","volume":"10","author":"D Pandit","year":"2025","unstructured":"Pandit D, et al. PCNA in Pan-Cancer: A Prognostic Biomarker Unveiled Through a Data-Driven, Multidimensional Analysis of Transcriptomics, Immunity, and Functional Profiling. ACS Omega. 2025;10(26):28311\u201326.","journal-title":"ACS Omega"},{"issue":"5","key":"2135_CR50","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1101\/gad.2021311","volume":"25","author":"SE Polo","year":"2011","unstructured":"Polo SE, Jackson SP. Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. Genes Dev. 2011;25(5):409\u201333.","journal-title":"Genes Dev"},{"issue":"1","key":"2135_CR51","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","volume":"6","author":"R Huang","year":"2021","unstructured":"Huang R, Zhou PK. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduct Target Ther. 2021;6(1):254.","journal-title":"Signal Transduct Target Ther"},{"key":"2135_CR52","doi-asserted-by":"crossref","unstructured":"Alaa Eldeen M et al. Oncogenic Potential of Replication Factor C Subunit 4: Correlations with Tumor Progression and Assessment of Potential Inhibitors. Pharmaceuticals (Basel), 2024. 17(2).","DOI":"10.3390\/ph17020152"},{"issue":"8","key":"2135_CR53","doi-asserted-by":"publisher","first-page":"692","DOI":"10.21037\/atm-21-1523","volume":"9","author":"X Qiu","year":"2021","unstructured":"Qiu X, et al. Forkhead box O1 targeting replication factor C subunit 2 expression promotes glioma temozolomide resistance and survival. Ann Transl Med. 2021;9(8):692.","journal-title":"Ann Transl Med"},{"issue":"1","key":"2135_CR54","doi-asserted-by":"publisher","first-page":"19602","DOI":"10.1038\/s41598-023-46651-6","volume":"13","author":"M Oshima","year":"2023","unstructured":"Oshima M, et al. Identification of DNA damage response-related genes as biomarkers for castration-resistant prostate cancer. Sci Rep. 2023;13(1):19602.","journal-title":"Sci Rep"},{"issue":"9","key":"2135_CR55","doi-asserted-by":"publisher","first-page":"4928","DOI":"10.1093\/nar\/gkaa255","volume":"48","author":"S Giovannini","year":"2020","unstructured":"Giovannini S, et al. ATAD5 deficiency alters DNA damage metabolism and sensitizes cells to PARP inhibition. Nucleic Acids Res. 2020;48(9):4928\u201339.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"2135_CR56","doi-asserted-by":"publisher","first-page":"7928","DOI":"10.18632\/oncotarget.23974","volume":"9","author":"O Hershkovitz-Rokah","year":"2018","unstructured":"Hershkovitz-Rokah O, et al. Network analysis of microRNAs, genes and their regulation in diffuse and follicular B-cell lymphomas. Oncotarget. 2018;9(8):7928\u201341.","journal-title":"Oncotarget"},{"issue":"12","key":"2135_CR57","doi-asserted-by":"publisher","first-page":"e0317025","DOI":"10.1371\/journal.pone.0317025","volume":"19","author":"S Lu","year":"2024","unstructured":"Lu S, et al. Correction: Long non-coding RNA SNHG17 may function as a competitive endogenous RNA in diffuse large B-cell lymphoma progression by sponging miR-34a-5p. PLoS ONE. 2024;19(12):e0317025.","journal-title":"PLoS ONE"},{"issue":"1","key":"2135_CR58","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1007\/s11033-025-11094-x","volume":"52","author":"MJ Iqbal","year":"2025","unstructured":"Iqbal MJ, et al. Mapping the non-coding RNA landscape in ataxia telangiectasia: a scoping review of ATM dependent miRNA and lncRNA dysregulation. Mol Biol Rep. 2025;52(1):998.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"2135_CR59","doi-asserted-by":"publisher","first-page":"12414","DOI":"10.1038\/s41598-025-96140-1","volume":"15","author":"Y Ueda","year":"2025","unstructured":"Ueda Y, et al. Liver quad culture chip as a model for radiation injury research. Sci Rep. 2025;15(1):12414.","journal-title":"Sci Rep"},{"issue":"2","key":"2135_CR60","doi-asserted-by":"publisher","first-page":"102490","DOI":"10.1016\/j.omtn.2025.102490","volume":"36","author":"L Wu","year":"2025","unstructured":"Wu L, et al. Whole-transcriptome sequencing in neural and non-neural tissues of a mouse model identifies miR-34a as a key regulator in SMA pathogenesis. Mol Ther Nucleic Acids. 2025;36(2):102490.","journal-title":"Mol Ther Nucleic Acids"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02135-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02135-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02135-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:03:33Z","timestamp":1779667413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02135-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2135"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02135-1","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no financial or non-financial conflicts of interest","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was approved by the Ethics Committee of the First People\u2019s Hospital of Changzhou (Approval No: 2025 (education) CL034-01) and was conducted in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}}],"article-number":"227"}}